Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 2019

View Archived Issues

Hormonal obesity promoter identified

Drugs blocking "hugs" could fight fibrosis

Kinases and chemo

Results from dose-selection trial of H56:IC31 vaccine candidate in tuberculosis-endemic populations

Fever directs traffic to strengthen immune response

Blincyto approved for expanded indication in Europe

I-Mab receives FDA IND clearance for phase I study of TJD-5

Rocket Pharmaceuticals announces FDA clearance of IND for RPA-501 gene therapy

Voclosporin ophthalmic solution demonstrates statistically superior efficacy versus Restasis

Margetuximab plus pembrolizumab shows promising activity in HER2+ (IHC3+) gastric carcinoma

Ramucirumab plus nivolumab shows promising antitumor activity in phase I/II NivoRam study

KemPharm presents phase I data for KP-415

Daiichi Sankyo presents phase I data for DS-8895a in patients with solid tumors

SM-88 appears safe and active in phase II trial in metastatic pancreatic adenocarcinoma

Sorrento reports phase Ib interim analysis with resiniferatoxin in knee osteoarthritis pain

Esteve Pharmaceuticals presents new analgesics

AstraZeneca divulges new SERDs

Phase III study of NexoBrid meets primary and secondary endpoints

Bio-Thera begins phase III study of tocilizumab biosimilar BAT-1806

Beijing Foreland Pharma identifies lysophospholipid S1P1 receptor ligands

Ultragenyx reports long-term extension study results for UX-007 in LC-FAOD

New PRMT5 inhibitors presented by Bayer

Shenzhen Targetrx Biotechnology patents EGFR double-mutant inhibitors

PROLONG study of OBE-022 in preterm labor advances into part B following successful part A

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...